NF2 and cancer: Figure 3C describes an unusual CA-Pheo that arose in a patient with a likely germline mutation in the MEN1 gene that also featured a TSC2 inactivating mutation potentially treatable with mTOR inhibition. For the CA-Para patients, the targetable GA included FGFR1 (7%, primarily amplifications) and NF1, PTEN, NF2 and CDK4 (all 2%) (Figure 2B). An NF2 mutation-driven CA-Para originating in the right ear canal in a 35-year-old Caucasian man is shown in Figure 3D. NF2 driven tumors have been shown to respond to combinations of mTOR inhibitors and MEK inhibitors.